Dr. Roué on the Rationale for Evaluating TG-1701 in Ibrutinib-Resistant MCL Models

Video

Gaël Roué, PhD, discusses the rationale to evaluate the novel irreversible BTK inhibitor TG-1701 in preclinical models of ibrutinib-resistant mantle cell lymphoma.

Gaël Roué, PhD, senior scientist at Josep Carreras Leukaemia Research Institute, discusses the rationale to evaluate the novel irreversible BTK inhibitor TG-1701 in preclinical models of ibrutinib (Imbruvica)-resistant mantle cell lymphoma (MCL).

During the 2020 AACR Virtual Meeting, a study was presented showing activity with TG-1701 in combination with ublituximab and umbralisib in ibrutinib-resistant MCL models.

There is some debate regarding whether combining BTK inhibitors with CD20-directed antibodies is a lucrative strategy in MCL, says Roué. However, it is thought that inhibiting the BTK pathway may lead to a downregulation of CD20, which could antagonize anti-CD20 activity.

Additionally, the study showed that TG-1701 did not impair anti-CD20–mediated antibody-dependent cellular cytotoxicity or phagocytosis unlike ibrutinib, which partially antagonized rituximab (Rituxan) activity.

Related Videos
Núria Agustí Garcia, MD
Mikkael A. Sekeres, MD, MS
Benjamin Levy, MD
Alessandra Ferrajoli, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS